Inclusion Criteria:

- Patients newly diagnosed as HCC according to European Association for Study of the
Liver criteria.

- BCLC stage B

- Child-Pugh class A

- ECOG performance status of 0

- Etiology: Hepatitis B virus(HBV) infection

- Written informed consent (approved by the Institutional Review Board [IRB]obtained
prior to any study specific screening procedures

- Patient must be able to comply with the protocol

- Age 18-80 years

- Haematology:Absolute neutrophil count (ANC) > 1 x 109/L, Platelet count > 40 x 109/L,
Haemoglobin > 9 g/dL (may be transfused to maintain or exceed this level) Prothrombin
time international normalized ratio < 1.5

- Biochemistry:Total bilirubin < 2 mg/dL Serum creatinine < 1.5 x the upper limit of
normal

- Life expectancy of > 3 months

Exclusion Criteria:

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5 x the upper
limit of normal

- Other severe concomitant disease that may reduce life expectancy

- uncontrolled hypertension

- Pregnancy (positive serum pregnancy test) or lactation

- Uncontrolled hypertension

- Serious, non-healing wound, ulcer, or bone fracture

- Currently or recent (within the 30 days prior to starting study treatment) treatment
of another investigational drug or participation in another investigational study

- Clinically significant (i.e. active) cardiovascular disease for example
cerebrovascular accidents ( ≤ 6 months prior to study entry), myocardial infarction (
≤ 6 months prior to study entry), unstable angina, New York Heart Association (NYHA)
grade II or greater congestive heart failure, serious cardiac arrhythmia requiring
medication

- Evidence of other disease, metabolic dysfunction, physical examination finding, or
clinical laboratory finding giving reasonable suspicion of a disease or condition
that contraindicates use of Sorafenib/TACE or patient at high risk from treatment
complications